Vaccines against SARS‐CoV‐2 are safe to administer in patients with antibodies to pegaspargase
OBJECTIVE: Allergic reactions to pegaspargase during ALL therapy are typically due to antibodies against polyethylene glycol (PEG), which is also used as a stabilizing agent in mRNA‐based SARS‐CoV‐2 vaccines. To evaluate the safety of these vaccines in patients with anti‐pegaspargase antibodies. MET...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349948/ https://www.ncbi.nlm.nih.gov/pubmed/35837830 http://dx.doi.org/10.1002/cam4.5011 |